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11 indirect comparisons). All the results were obtained from
indirect comparison. Dutasteride, compared to ﬁnasteride, sig-
niﬁcantly improved AUA-SI score (WMD = 1.53), and inﬂuenced
PSA concentration (WMD = −1.33). Average costs (including
drugs costs, complications and prostatic cancer treatment) and
effects (LY with no surgery/prostatic cancer) were per patient:
dutasteride 5655 PLN/6.23 LY; ﬁnasteride 6081 PLN/5.13 LY.
Dutasteride was dominant therapy compared with ﬁnasteride
(more effective and less costly). CONCLUSIONS: Dutasteride is
clinically more effective and more cost-effective in BPH com-
pared to both placebo and ﬁnasteride.
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OBJECTIVE: To evaluate the cost-effectiveness of IMSS formu-
lary drugs for preventing uterine atony in patients with risk
factors. METHODS: A ﬁnal report of a randomized pragmatic
clinical trial at the Mexican Institute of Social Security (IMSS) is
presented. Carbetocine and oxytocin are the only drugs within
IMSS formulary for preventing uterine atony. Risk factor
included fetal macrosomia, polyhydramnios, low insertion of the
placenta, multiple gestation, prolonged labor, uterine myomas
and chorioamnionitis. The effectiveness was deﬁned as the reduc-
tion of the number of patients with uterine atony. The use of
resources was obtained from the clinical trial and the costs were
gotten from ﬁnancial information from IMSS, and are expressed
in US 2006 dollars. Squared ji and U de Mann Whitney test were
used. Univariate and probabilistic sensitivity analyses, a Monte
Carlo microsimulation with 10,000 iterations was performed
using probability distribution data from the clinical trial. A 95%
conﬁdence interval of ICER was calculated by ellipse method.
RESULTS: Seventy-seven patients received carbetocine and 75
oxytocin. Both groups had similar obstetrics and sociodemo-
graphic characteristics. Uterine atony was reported in 19% in
the oxytocin group compared to 8% in the carbetocine one (p <
0.0001). Multiple gestation was the most frequent diagnosis,
35% (p < 0.0001). Bleeding was less than 500 mL in the carbe-
tocine group and 500–1000 mL in the oxytocin one (p < 0.0001).
Mean cost per patient treated with carbetocine was $3525 vs.
$4054 for oxytocine (p < 0.0001). Mean cost-effectiveness ratio
for oxytocin was $4944, while for carbetocine $3874; ICER
showed that carbetocine was dominant. Univariate analysis sup-
ported those results. The acceptability curve and health net ben-
eﬁts showed that carbetocine group was superior independently
of WTP. CI 99% by ellipse method showed that carbetocine was
dominant in 100% of cases. CONCLUSIONS: Carbetocine was
dominant in preventing uterine atony in patients with risk
factors.
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OBJECTIVE: As part of a health technology assessment com-
paring a single-embryo-transfer (SET) in In-Vitro Fertilization
(IVF) with the traditional double-embryo-transfer (DET) used
today in Denmark the cost-effectiveness of SET was compared
with DET. The aim was to inform decision-makers about the eco-
nomic consequences of the eventual adoption of a SET policy in
Denmark. METHODS: The analysis was based on prospective
collection of resource use and costs of singletons and twins. A
total of 213 pregnant women at the fertility clinic have been
reporting resource use (health care and so-cial sector), and days
absent from work in cost diaries during a year (from pregnancy
scan to until three months after delivery). Clinical effectiveness
data of SET and DET came from a Scandinavian multi-center
trial, and a recent Cochrane review. RESULTS: The advantage
of SET is delivery of few expensive twins compared with DET
(25%). The cost-effectiveness per clinical pregnancy of DET
(DKK 115,321 per clinical pregnancy and DKK 120,934 per
delivery) was lower than using that of SET (DKK 131,446 per
clinical pregnancy and DKK 149,833 per delivery). The cost-
effectiveness of DET is explained by a higher clinical pregnancy
rate, a higher rate of delivery, and more children born. However,
DET is also a more expen-sive alternative for the average patient
treated, because of higher costs for delivery and neonatal care.
The extra cost per patient using DET is around DKK 82,000 per
delivery and around DKK 50,000 per extra child born using
DET. CONCLUSION: The cost per delivery and per child born
is lower using DET compared with SER. However, the total costs
for DET is higher due to higher antenatal, delivery and neona-
tal costs, as well as production loss. A higher rate of twin deliv-
eries using DET explains this. These extra costs using the more
effective DET policy are moderate.
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Quantitative information on the management of PHN, a com-
plication of HZ, is scarce, with the most recent data from 1975.
With the imminent arrival of a prophylactic Zoster vaccine, it is
important to document the burden of PHN in the UK. OBJEC-
TIVES: To estimate the proportion of HZ patients developing
PHN, the duration, resource use and costs of PHN sufferers,
using two deﬁnitions: pain persisting one (1-month deﬁnition) or
three months (3-month deﬁnition) after HZ onset. METHODS:
Records of immuno-competent individuals of ≥50 years, diag-
nosed with HZ between 2000 and 2005, and with ≥1-year
follow-up were selected from the UK General Practice Research
Database (GPRD). PHN episodes were identiﬁed by formal diag-
nosis and prescriptions of typical neuropathic pain medications.
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Duration was estimated from the number of treatment days per
patient. Resource use (medications, physicians visits, referrals
[excluding hospitalisations]) were retrieved from patients’
medical records. Economic analyses were performed to estimate
the average direct cost of PHN management from the National
Health Service (NHS) perspective. RESULTS: 25,002 patients
with HZ were included in the analyses. Mean age was 67.9 years,
61.1% were females. One-month deﬁnition: 19.5% (95%CI
19.0%; 20.0%) of patients developed PHN, 65.4% were
females; mean age was 71.2 years. Three-month deﬁnition:
13.7% (95%CI 13.2%; 14.1%) of patients developed PHN,
66.6% were females; mean age was 71.1 years. The mean PHN
duration was 7.5 and 9.0 months using the 1 and 3-month def-
initions respectively. The mean direct cost of PHN management
per episode was £284.38 and £340.04 for the NHS (1 and 
3-months deﬁnitions) increasing with severity (mild: £166.62,
moderate: £317.97, severe: £519.62 for the 1-month deﬁnition).
CONCLUSION: This study conﬁrms that PHN episodes remain
frequent and costly sequelae of HZ. Therefore, the future im-
plementation of a prophylactic Zoster vaccine is expected to 
signiﬁcantly decrease the economic burden of PHN.
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In France, children represent about 15% of GPs’ consultations.
The reasons for the doctor-child encounter have not yet been
extensively studied, and no research gave insights into the eco-
nomic burden of children care in general practice. OBJECTIVES:
This study aimed to: 1/ provide a descriptive analysis of the main
reasons for encounter, 2/ to examine the breakdown of the cost
of drugs prescribed and 3/ to estimate the economic burden of
drugs for children care in general practice in 2003 (the preva-
lence method was used). METHODS: We carried out an obser-
vational study in a representative sample of 922 French GPs
(BKL-Thalès® panel). We observed 60 consecutive visits per
doctor and registered data concerning all the children’ visits
during this period of time. Patients’ demographics, reasons for
encounter and related treatments were collected directly during
the consultation (patient management software). RESULTS: A
total of 6652 consultations out of 50,848 (13.08%) concerned
children (up to 15 years old). They were on average 6.8 ± 4.3
years old (29.2% were 3 or less), 52.1% were males, 11.1% of
them consulted the GP for the ﬁrst time, only 1.3% had a chronic
illness. The main reasons for encounter were respiratory tract
infections in 54.8% of cases, vaccination or routine exam and
prevention in 13.6%, abdominal complaint in 4.3% and der-
matosis in 4.1%. The top 3 of the cost of drugs prescribed was:
antibiotics with 21.7% of the costs (€12,652 in the sample), local
treatment for URTI with 19.9% (€11,575) and vaccines with
11.8% (€6898). The economic burden of drugs for children care
in general practice was estimated at €179.6 million for the year
2003. CONCLUSION: We identiﬁed an area of high expendi-
ture where inefﬁciencies may exist and saving be made; this
remains to be explored.
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OBJECTIVES: Due to future demographic change health policy
has to focus on elderly people. The aim of this study was to
measure service utilization and direct health care costs and its
predictors for the age group 75+ in Germany from the societal
perspective. METHODS: A bottom-up costing study was con-
ducted using a representative cross-sectional population sample.
Study subjects (N = 452) were recruited through 20 general prac-
titioners in Saxony. The main instrument was a questionnaire of
service utilization and costs administered by an interviewer. The
Chronic-Disease-Score (CDS) was calculated based on reported
drug utilization. Predictors were derived by multivariate regres-
sion models. RESULTS: Study subjects caused average direct
health care costs of EUR 3868 in 2004. This included: inpatient
treatment 36%, pharmaceuticals 28%, outpatient services 14%,
home care 9%, medical supply and dentures 6%, nonphysician
providers 4%, assisted living 1% und transport 2%. Female
gender, a higher level of vocational training and a higher CDS
were predictors of higher total costs. Age and family status had
no signiﬁcant inﬂuence. Within the 3 month preceding the inter-
view study subjects utilized at least once: pharmaceuticals 98%,
outpatient services 98%, nonphysician providers 29%, home
care (12 months) 23%, inpatient treatment (6 months) 18%,
medical supply and dentures 16%, assisted living (6 months) 4%
and transport 54%. 54% of the study subjects accounted for
90% of total costs. CONCLUSIONS: Elderly people in the age
group 75+ cause substantial direct health care costs in particu-
lar for inpatient care and pharmaceuticals. Measured costs are
almost twice as high as the average expenses paid per insured
person by compulsory sickness funds and long-term care insur-
ance in 2004, in Germany. Further research should focus on
heavy users, thereby concentrating on the two main cost cate-
gories, which account for 64% of the average direct costs.
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OBJECTIVES: Several studies forecasting health care expendi-
tures (HCE) predict continuously increasing expenses due to at
least three factors: ageing, technical progress, and prices. The aim
of this study is to identify the effects of selected inﬂuencing factors
on the expenditures of prescribed drugs (EPD), e.g. the share of
65 aged and older (POP65), doctors’ consultations (DOC), and
R&D expenditures of pharmaceutical industry (PHARM_R&D).
As EPD have grown faster than any other major components of
HCE since the late 1990s, cross-national differences in pharma-
ceutical expenditures are of great interest. METHODS: With
panel data of seven countries (Australia, Canada, Finland, France,
Germany, Japan, and US) from 1991 to 2001 a dynamic panel
estimator, namely the ﬁrst-differenced General Method of
Moments (GMM) has been applied to test the following hypothe-
ses. If POP65 as well as DOC, and PHARM_R&D increase, then
EPD will increase. If the rest life expectancy at age 65 (LIFEXP65)
as well as PHARM_R&D increase, then innovations instru-
mented as patent applications (PAT_AP) will increase. RESULTS:
The one-period lagged EPD (0.646; 99%CI) was highly signiﬁ-
cant, POP65 (0.018; 90%CI) and DOC (−0.024; 95%CI) 
were signiﬁcant, and PHARM_R&D was marginally signiﬁcant
